Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.verified

TSHA

Price:

$3.24

Market Cap:

$605.94M

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy tr...[Read more]

Industry

Biotechnology

IPO Date

2020-09-24

Stock Exchange

NASDAQ

Ticker

TSHA

The PE Ratio as of May 2024 (TTM) for Taysha Gene Therapies, Inc. (TSHA) is -3.38

According to Taysha Gene Therapies, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.38. This represents a change of 112.22% compared to the average of -1.59 of the last 4 quarters.

Taysha Gene Therapies, Inc. (TSHA) Historical PE Ratio (quarterly & annually)

How has TSHA PE Ratio performed in the past?

The mean historical PE Ratio of Taysha Gene Therapies, Inc. over the last ten years is -162.81. The current -3.38 PE Ratio has changed 107.60% with respect to the historical average. Over the past ten years (40 quarters), TSHA's PE Ratio was at its highest in in the December 2023 quarter at 1.73. The PE Ratio was at its lowest in in the December 2019 quarter at -81.84.

Quarterly (TTM)
Annual

Average

-162.81

Median

-2.50

Minimum

-798.24

Maximum

-0.59

Taysha Gene Therapies, Inc. (TSHA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Taysha Gene Therapies, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 214.52%

Maximum Annual PE Ratio = -0.59

Minimum Annual Increase = -98.63%

Minimum Annual PE Ratio = -798.24

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.84214.52%
2022-0.59-76.57%
2021-2.50-77.07%
2020-10.90-98.63%

Taysha Gene Therapies, Inc. (TSHA) Average PE Ratio

How has TSHA PE Ratio performed in the past?

The current PE Ratio of Taysha Gene Therapies, Inc. (TSHA) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.64

5-year avg

-162.81

10-year avg

-162.81

Taysha Gene Therapies, Inc. (TSHA) PE Ratio vs. Peers

How is TSHA’s PE Ratio compared to its peers?

Taysha Gene Therapies, Inc.’s PE Ratio is less than Biomea Fusion, Inc. (0), less than Stoke Therapeutics, Inc. (-3.10), greater than Akero Therapeutics, Inc. (-6.14), greater than Homology Medicines, Inc. (-6.06), less than Gossamer Bio, Inc. (-0.01), less than X4 Pharmaceuticals, Inc. (-0.81), less than Inozyme Pharma, Inc. (-1.40), greater than Terns Pharmaceuticals, Inc. (-3.66), greater than Day One Biopharmaceuticals, Inc. (-4.90), greater than HOOKIPA Pharma Inc. (-5.71), less than Monte Rosa Therapeutics, Inc. (-2.11), less than Cabaletta Bio, Inc. (-1.85), greater than Larimar Therapeutics, Inc. (-7.00), greater than Alector, Inc. (-8.41), greater than Shattuck Labs, Inc. (-3.88), greater than C4 Therapeutics, Inc. (-4.45), less than Eliem Therapeutics, Inc. (-2.97), greater than Prelude Therapeutics Incorporated (-14.10), less than null (-2.47),

Build a custom stock screener for Taysha Gene Therapies, Inc. (TSHA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Taysha Gene Therapies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Taysha Gene Therapies, Inc. (TSHA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Taysha Gene Therapies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Taysha Gene Therapies, Inc.'s PE Ratio?

How is the PE Ratio calculated for Taysha Gene Therapies, Inc. (TSHA)?

What is the highest PE Ratio for Taysha Gene Therapies, Inc. (TSHA)?

What is the 3-year average PE Ratio for Taysha Gene Therapies, Inc. (TSHA)?

What is the 5-year average PE Ratio for Taysha Gene Therapies, Inc. (TSHA)?

How does the current PE Ratio for Taysha Gene Therapies, Inc. (TSHA) compare to its historical average?